SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is trending amidst widespread community alarm, with a dominant narrative of a 'rugpull' and declarations that 'crypto is dead' following significant price declines. Many holders are expressing extreme frustration, labeling the asset a 'scam' and criticizing its founder, with some urging a sell-off and a pivot to other assets like AI stocks or XRP, while a smaller contrarian group advocates buying the deep dip.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust is trending as global market participants react to reports of soaring physical silver prices in Shanghai and impending Chinese export restrictions. The community is actively discussing a potential "silver squeeze," fueled by concerns over structural supply deficits and rising industrial demand from sectors like EVs and AI data centers. While many anticipate significant further upside and a re-rating of silver's value, some observers warn of potential near-term volatility after its rapid ascent.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot (DOT) is generating buzz as its DAO recently capped the token supply at 2.1 billion with future emission halvings, fundamentally altering its tokenomics towards scarcity. This significant shift, combined with ongoing Polkadot 2.0 upgrades enhancing elastic scaling, is sparking active community discussion about the network's long-term potential and attracting renewed interest from both developers and institutional entities in the interoperable Web3 space.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is trending due to a massive data breach affecting millions of South Korean users, sparking intense regulatory scrutiny and significant public backlash against the company's leadership. The community is sharply divided between those fearing severe government penalties and consumer boycotts, and others who see the recent sell-off as an oversold buying opportunity given Coupang's entrenched e-commerce dominance in the region.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid highly polarized community sentiment, with many debating whether recent price drops are a "Christmas dump" or a strategic institutional accumulation phase. Despite reported ETF inflows and a strong belief in its long-term utility for global finance, frustration over perceived price manipulation is driving heated exchanges between staunch bulls and exasperated bears.

AABG Token

AABBG Crypto is trending due to upcoming catalysts, including a January 2026 corporate update detailing mining and digital currency projects, alongside the highly anticipated launch of its silver-backed AABBS token and next-generation wallet. The community is actively discussing the company's expanding gold and silver production, boosted by new rGO recovery technology, amidst a surge in precious metal prices. Investors remain vigilant, emphasizing perceived market manipulation and the company's ongoing legal action to protect shareholder value.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond (Beyond, Inc.) is trending intensely, fueled by anticipation for its upcoming earnings, a recent merger acquisition, and plans for a potential public listing of its tZERO blockchain asset. While some in the community foresee a significant turnaround and short squeeze from these developments, others remain highly skeptical, highlighting ongoing concerns over cash burn, dilution, and the rebranded entity's uncertain path to sustained profitability.

TerraClassicUSD

TerraClassicUSD (USTC) is a focal point of discussion following the sentencing of Do Kwon, with the community actively speculating on its future. Many believe this development could pave the way for a potential repeg and the broader revitalization of the Terra Luna ecosystem, alongside ongoing efforts like supply burns and network upgrades.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending due to strong Black Friday sales results, signaling accelerating Gross Merchandise Value growth, and recent 'Buy' ratings from analysts projecting significant upside. The community is actively discussing the company's clear roadmap towards profitability by 2027 and its strategic advantage as the 'Amazon of Africa' in the continent's rapidly expanding e-commerce market. This positive sentiment is further bolstered by increasing institutional interest.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat (WIF) is currently a hotbed of intense debate, with many traders expressing extreme frustration over its volatile price action and perceived inability to sustain gains. Despite widespread bearish sentiment and accusations of manipulation, a dedicated portion of the community remains highly optimistic, actively accumulating and anticipating a significant breakout or 'parabolic move' in anticipation of an altcoin season.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Artelo Biosciences, Inc. (ARTL) surged 57% on Monday afternoon after the company announced positive preclinical data highlighting the potential of its drug candidate in treating depression and anxiety.The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with leading antidepressant medication, Sertraline (Zoloft).ART12.11 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.artelobio.com/news-events/press-releases/detail/153/artelo-biosciences-announces-positive-preclinical-efficacy">improved</a> sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels.However, unlike Sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, the company added.<a href="https://stocktwits.com/symbol/ARTL">Artelo</a> added that the findings demonstrate the candidate’s potential as a candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing selective serotonin reuptake inhibitor therapies like Sertraline.ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP).Prior preclinical research studies in animals with ART12.11 demonstrated greater behavioral and pharmacokinetic results compared to Cannabidiol or Epidiolex.Artelo CEO Gregory D Gorgas said that although strong antidepressant effects were noted with ART12.11 in prior studies, the company is “especially encouraged” by these new comparative findings.On Stocktwits, retail sentiment around Artelo, however, fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_12_27_08_PM_png_b2e63d4064.webp" alt="ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>ARTL stock is up by about 148% this year and by about 99% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-buying-hit-3-4-trillion-in-the-first-half-of-2025-yet-market-chatter-has-faded/chFtYldR5fx">Retail Buying Hit $3.4 Trillion In The First Half Of 2025, Yet Market Chatter Has Faded</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 

Equity

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 


Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.ART26.12 is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage caused by certain chemotherapy drugs, leading to sensory, motor, or autonomic dysfunction.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107392/0/en/Artelo-Biosciences-Announces-Positive-First-in-Human-Data-for-ART26-12-a-Novel-Non-Opioid-Treatment-Candidate-for-Persistent-Pain.html">said</a> that all adverse events identified during the in-human trial were mild, transient, and self-resolving. Furthermore, the study demonstrated predictable pharmacokinetics for the drug.Pharmacokinetics is defined as the quantitative analysis of the processes of drug absorption, distribution, and elimination that determine the time course of drug action in response to an administered drug dose.The company said that complete dose-exposure profiles were explored, and tests confirmed dose-dependent, linear absorption across the evaluated range.Andrew Yates, Chief Scientific Officer at Artelo, said that the company is “particularly pleased” that the safety and pharmacokinetic profile generated from ART26.12’s non-clinical studies translated well to the human experience.According to Artelo, the chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 2030, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia.The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.On Stocktwits, retail sentiment around ARTL jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_30_at_1_46_11_PM_png_54bfa7b48c.webp" alt="ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits" width="624" height="62"><figcaption>ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, flagged that the company will need cash to progress its pipeline, and hence, dilution is likely.<stembedurl>https://stocktwits.com/ElPutoToro/message/619463192</stembedurl>The company had cash and investments totaling only $0.7 million as of the end of the first quarter.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up by about 135% this year and by about 85% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q2-deliveries-expected-to-fall-below-consensus-jpmorgan-underscores-sizable-shortfall/chmZF6zRR7Q">Tesla Q2 Deliveries Expected To Fall Below Consensus, JPMorgan Underscores A ‘Sizable’ Shortfall</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial

Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.

The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.


Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Current Price	$1.58
Prev Close	$1.60
Open	$1.56
Dividend Yield	0.00%
50-Day Moving Average	$2.30
Beta	0.64
Avg. Volume	556,289.79
PE Ratio	-0.08

52-Week High	$28.60
52-Week Low	$1.48
Market Capitalization	$3.19M
EPS (Annual)	-$18.29
Price to Book	-3.88
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ARTL News

ARTLArtelo Biosciences Inc